Redsense Medical AB (publ)
Redsense Medical AB (publ) develops, markets, and sells monitoring systems for medical treatments primarily in Europe and the United States. The company offers Redsense System, a medical technology product that is used for monitoring and alarming in the event of blood leakage in connection with a hemodialysis treatment. It also provides Redsense Clamp, which clamps the bloodline to stop blood flo… Read more
Redsense Medical AB (publ) (RDSNF) - Net Assets
Latest net assets as of June 2024: $30.16 Million USD
Based on the latest financial reports, Redsense Medical AB (publ) (RDSNF) has net assets worth $30.16 Million USD as of June 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($34.38 Million) and total liabilities ($4.23 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $30.16 Million |
| % of Total Assets | 87.71% |
| Annual Growth Rate | 11.49% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 182.33 |
Redsense Medical AB (publ) - Net Assets Trend (2019–2023)
This chart illustrates how Redsense Medical AB (publ)'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Redsense Medical AB (publ) (2019–2023)
The table below shows the annual net assets of Redsense Medical AB (publ) from 2019 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | $23.09 Million | -14.93% |
| 2022-12-31 | $27.15 Million | -27.59% |
| 2021-12-31 | $37.49 Million | -48.78% |
| 2020-12-31 | $73.20 Million | +389.71% |
| 2019-12-31 | $14.95 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Redsense Medical AB (publ)'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 5077307700.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $8.13 Million | 35.19% |
| Other Components | $14.97 Million | 64.81% |
| Total Equity | $23.09 Million | 100.00% |
Redsense Medical AB (publ) Competitors by Market Cap
The table below lists competitors of Redsense Medical AB (publ) ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Cazaly Resources Ltd
AU:CAZ
|
$5.24 Million |
|
EV RESOURCES LTD.
F:R1EA
|
$5.24 Million |
|
Comet Industries Ltd
V:CMU
|
$5.24 Million |
|
Dataworks Group Ltd
AU:DWG
|
$5.24 Million |
|
Pan Asia Footwear Public Company Limited
BK:PAF
|
$5.24 Million |
|
NINtec Systems Limited
NSE:NINSYS
|
$5.24 Million |
|
ISE Commerce Company Limited
KQ:069920
|
$5.23 Million |
|
REABOLD RESOURCES LS-001
F:AWL1
|
$5.23 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Redsense Medical AB (publ)'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from 27,149,000 to 23,095,000, a change of -4,054,000 (-14.9%).
- Net loss of 4,513,000 reduced equity.
- Other factors increased equity by 459,000.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-4.51 Million | -19.54% |
| Other Changes | $459.00K | +1.99% |
| Total Change | $- | -14.93% |
Book Value vs Market Value Analysis
This analysis compares Redsense Medical AB (publ)'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.31x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 0.42x to 0.31x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $1.23 | $0.51 | x |
| 2020-12-31 | $5.21 | $0.51 | x |
| 2021-12-31 | $2.67 | $0.51 | x |
| 2022-12-31 | $1.93 | $0.51 | x |
| 2023-12-31 | $1.64 | $0.51 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Redsense Medical AB (publ) utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -19.54%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -18.08%
- • Asset Turnover: 0.94x
- • Equity Multiplier: 1.15x
- Recent ROE (-19.54%) is above the historical average (-23.87%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -33.93% | -38.23% | 0.70x | 1.27x | $-6.57 Million |
| 2020 | -12.34% | -62.56% | 0.18x | 1.08x | $-16.35 Million |
| 2021 | -21.26% | -85.15% | 0.22x | 1.15x | $-11.72 Million |
| 2022 | -32.26% | -61.07% | 0.47x | 1.13x | $-11.47 Million |
| 2023 | -19.54% | -18.08% | 0.94x | 1.15x | $-6.82 Million |
Industry Comparison
This section compares Redsense Medical AB (publ)'s net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $694,749,556
- Average return on equity (ROE) among peers: -25.46%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Redsense Medical AB (publ) (RDSNF) | $30.16 Million | -33.93% | 0.14x | $5.24 Million |
| Advanced Biomedical Technologies Inc (ABMT) | $-4.46 Million | 0.00% | 0.00x | $14.18K |
| Abbott Laboratories (ABT) | $4.82 Billion | 39.04% | 1.31x | $191.37 Billion |
| Acarix AB (publ) (ACIXF) | $1.93 Million | -127.02% | 0.21x | $26.42 Million |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-72.62 Million | 0.00% | 0.00x | $4.05 Million |
| Adm Tronics Unltd (ADMT) | $-12.69K | 0.00% | 0.00x | $3.17 Million |
| Aethlon Medical Inc (AEMD) | $-3.07 Million | 0.00% | 0.00x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $126.58 Million | -80.56% | 0.52x | $732.88K |
| Adapthealth Corp (AHCO) | $2.07 Billion | 7.56% | 1.54x | $914.25 Million |
| Allied Healthcare Products Inc. (AHPIQ) | $8.88 Million | -33.95% | 1.22x | $726.24 |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $3.39 Million | -59.65% | 0.38x | $9.18 Million |